On Friday, Beam Therapeutics Inc (NASDAQ: BEAM) opened higher 12.62% from the last session, before settling in for the closing price of $18.54. Price fluctuations for BEAM have ranged from $13.52 to $35.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.88% annually for the last half of the decade. Company’s average yearly earnings per share was noted 5.99% at the time writing. With a float of $91.26 million, this company’s outstanding shares have now reached $100.76 million.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Beam Therapeutics Inc is 9.79%, while institutional ownership is 101.29%. The most recent insider transaction that took place on Jul 30 ’25, was worth 991,667. In this transaction insider of this company sold 48,374 shares at a rate of $20.50, taking the stock ownership to the 2,073,665 shares. Before that another transaction happened on Jul 03 ’25, when Company’s Chief Medical Officer sold 876 for $20.12, making the entire transaction worth $17,625. This insider now owns 64,864 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -1.17 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.18) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.47% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Check out the current performance indicators for Beam Therapeutics Inc (BEAM). In the past quarter, the stock posted a quick ratio of 6.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.51, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -4.43 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Let’s dig in a bit further. During the last 5-days, its volume was 4.03 million. That was better than the volume of 2.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 75.86%.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 74.23%, which indicates a significant decrease from 99.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.08 in the past 14 days, which was lower than the 1.12 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.80, while its 200-day Moving Average is $21.86. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $21.63. Second resistance stands at $22.37. The third major resistance level sits at $23.83. If the price goes on to break the first support level at $19.43, it is likely to go to the next support level at $17.97. The third support level lies at $17.23 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are currently 101,162K shares outstanding in the company with a market cap of 2.11 billion. Presently, the company’s annual sales total 63,520 K according to its annual income of -376,740 K. Last quarter, the company’s sales amounted to 8,470 K and its income totaled -102,290 K.
